Trial Profile
A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; Meningococcal vaccine group C conjugate; Tick-borne encephalitis vaccine
- Indications Encephalitis; Influenza virus infections; Meningococcal group C infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Novartis; Novartis Vaccines
- 07 Aug 2012 Additional locations [Belgium, Hungary, Italy] identified as reported by as reported by European Clinical Trials Database(Parent trial: EudraCT2007-003786-41).
- 25 Feb 2012 Planned patient number 1970 added as reported by European Clinical Trials Database (Extention trial: EudraCT2010-021644-18).
- 25 Feb 2012 Actual end date 19 Feb 2012 added as reported by European Clinical Trials Database (Extention trial: EudraCT2010-021644-18).